We are please to share a recent interview with Joerg Ahlgrimm, CEO of SK Pharmteco. In this conversation, Joerg discusses the company’s strategic expansion in peptides, their investments across Asia, Europe, and the US, and their recent partnership with Lotte Biologics to advance antibody drug conjugates. He also shares his vision for SK Pharmteco’s growth and leadership in the biotech CDMO space over the next few years.
TWENTYFOURSEVENBIOPHARMA